Vmbook Online ordering

Prothena Corporation Plc

Prothena Corporation Plc is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of protein immunotherapies for the treatment of diseases with high unmet medical need. The company's protetherapy platform is based on its proprietary antibody engineering, protein production and manufacturing capabilities.

Prothena's pipeline includes programs for neurological disorders such as Parkinson's disease and other related synucleinopathies, as well as inflammation and complement-mediated diseases. Its leading product candidate is PRTA-4021r (also known as Birtamimab), an anti-alpha-synuclein antibody for the treatment of Parkinson's disease and other synucleinopathies.

Prothena's common stock is listed on the Nasdaq Global Select Market under the ticker symbol "PRTA". As of February 2023, the company has a market capitalization of around $600 million.

In the past 52 weeks, the stock price of Prothena has ranged from a low of $13.65 per share to a high of $28.34 per share. The company has collaboration and license agreements with major pharmaceutical companies such as Roche and Celgene.

Prothena has a team of experienced management and scientific leaders with expertise in drug discovery and development. However, like any biotechnology company, Prothena faces risks such as clinical trial failures, regulatory setbacks, and competition from other companies developing similar therapies. Investors in Prothena should carefully consider these risks when evaluating the company's prospects.

Please note that the information provided above is subject to change and should be verified with the latest financial reports and filings by the company.